Lucid Diligence Brief - BioPharma

Nurix Roche Bexobrutideg Deal | Lucid Diligence Brief

Roche’s collaboration with Nurix turns bexobrutideg into a multi-indication BTK…


Lucid Diligence Brief - BioPharma

Servier Edgewise Sevasemten Deal | Lucid Diligence Brief

Servier’s Edgewise acquisition puts sevasemten’s Becker muscular dystrophy data…


Biosimilars on the rise: they are just getting started

Biologics have revolutionized the management of previously intractable…


Privacy Preference Center